Sandoz agrees to $275M settlement in generic antitrust litigation
Sandoz has agreed to pay $275 million to settle multidistrict generic price-fixing claims brought by a group that includes some insurers and employee benefit plans. The deal doesn’t force Sandoz to ...
View ArticleMajor PBM reforms feature in Congress' year-end spending bill
An end-of-year spending bill will include major reforms to the ways pharmacy benefit managers operate, including significant new restrictions on the fees and rebates that have huge influence over the...
View ArticleJazz Pharmaceuticals CEO and co-founder announces retirement
Jazz Pharmaceuticals CEO Bruce Cozadd is ready to play his outro. On Monday, Cozadd announced plans to retire, nearly 22 years after co-founding Jazz and 15 years after becoming chief executive ...
View ArticleSiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M
About eight years after its Series B, a small biotech working on non-opioid treatments has raised its Series C to gather clinical proof of concept in acute and chronic pain. And it’s a big round ...
View ArticleAurion’s eye cell therapy improves vision in small study, plots Phase 3 trial
Aurion Biotech said its cell therapy for treating the cornea improved vision at the highest dose, which it plans to further study in a Phase 3 trial beginning later next year. The Seattle-based biotech...
View ArticleExclusive: Insitro finds new ALS drug target in Bristol Myers deal
The AI-focused biotech insitro is advancing a new idea to potentially treat ALS, one of the most intractable and brutal diseases. The South San Francisco-based startup has identified a new drug target...
View ArticleNovo Nordisk partners with Broad Institute spinout Photys after the startup's...
Novo Nordisk is exploring a new class of small molecule drugs that act as matchmakers between two proteins in partnership with a biotech startup called Photys Therapeutics. The companies will work on...
View ArticleNovartis and BioAge partner on longevity, exercise targets
BioAge Labs, which began nearly a decade ago as an anti-aging biotech and then turned to obesity this year, is going back to its roots and teaming up with Novartis to find new drug targets ...
View ArticleRing Therapeutics cuts workforce in latest round of layoffs
Ring Therapeutics, a startup looking to advance a new type of virus to deliver gene therapies, has let go "just under 50%" of its workforce, a spokesperson told Endpoints News Wednesday morning. "We...
View ArticleMerck’s long-awaited obesity move is an oral GLP-1 from China
Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though it's happening years after some of its big pharma peers. Like AstraZeneca did a year ago with ...
View ArticleTessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger
Plus, news about Sensorion, Soleno Therapeutics, Corvus and Hansa Biopharma: Tessera Therapeutics bags up to $50M for sickle cell disease R&D: The investment is part of Tessera’s new agreement with...
View ArticleBiosecure Act influence still felt even as China bill stalls
Last March, I received a flurry of texts and emails from readers. It was one of the strongest reactions I’ve ever gotten to an article. Endpoints News had just published my piece ...
View ArticleNovartis, AbbVie and PhRMA secure 340B court win in West Virginia
Novartis, AbbVie and industry group PhRMA on Tuesday notched a victory over a West Virginia law that would have required the companies to distribute drugs at reduced prices to an unlimited number of...
View ArticleUS drug spending surged to almost $450B in 2023
Popular weight loss and diabetes treatments contributed to a “faster overall growth” in prescription drug spending last year, according to a new report from the Centers for Medicare & Medicaid...
View ArticleDavid Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field
David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier this fall as CEO and chair of Ottimo Pharma, a preclinical biotech trying to take ...
View ArticleSangamo strikes brain-targeting AAV partnership with Astellas
Sangamo has made another gene therapy deal to keep the lights on for a few more months, extending its funding by another three months until at least mid-2025. On Thursday, the struggling California...
View ArticleRoche’s Parkinson’s drug flunks second mid-stage trial
Roche’s alpha-synuclein-targeting antibody has failed to slow the progression of motor symptoms in a mid-stage Parkinson’s disease test, marking the latest setback in a largely challenging year for the...
View ArticleEx-Color Health execs raise $10M to bring AI to pharma
Employees Nos. 1 and 2 of the $4.6 billion health tech startup Color Health have started their own company, aiming to tackle pharma's regulatory burden with generative AI. The San Francisco-based...
View ArticleVertex’s non-opioid pill disappoints in mid-stage chronic pain study
Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition, saying its non-opioid pain pill suzetrigine met the primary endpoint and...
View ArticleEndpoints winners and losers 2024: Best and worst biotech trends
Last year’s Endpoints News winners and losers list was such a hit that we decided to make it a tradition. As always, we’re keeping track of who’s ⬆️ and who’s ⬇️ in biopharma, the ideas ...
View Article